EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study

Carmen Lasa-Teja iD, Juan José Fernández-Cabero, Lara Sánchez-Bilbao iD, Javier Loricera iD, Iñigo González-Mazón iD, Carmen Álvarez-Reguera iD, Alba Herrero-Morant iD, Alfonso Corrales-Martínez, Virginia Portilla-González, Jose Luis Martín-Varillas iD, Laura Pérez-Garrido, Montserrat Santos-Gómez iD und 2 weitere

Journal of Clinical Medicine · 30.12.2025 · 15 (1) · 278

DOI: 10.3390/jcm15010278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.12.2025. Verfasst von Carmen Lasa-Teja und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, Instituto de Investigación Valdecilla (IDIVAL), 3900…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Janus kinase inhibitors (JAKi) are approved for the treatment of rheumatoid arthritis (RA), aiming to achieve clinical remission. Composite scores such as Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP) are influenced by subjective factors, and JAKi may impact these dimensions beyond inflammation. Ultrasound provides a sensitive and objective assessment of synovial activity.

Objective

To evaluate clinical and ultrasound-defined remission in RA patients treated with JAKi under routine care.

Methods

This cross-sectional study included all consecutive patients treated with baricitinib, filgotinib, tofacitinib, or upadacitinib between 1 November 2022 and 30 April 2023. Clinical remission was defined as DAS28-CRP and ultrasound remission as absence of power Doppler (PD) signal across a standardized 32-joint evaluation.

Results

We include 78 patients with established RA; 87.2% were female, with mean age of 59.5 ± 10.8 years and disease duration of 10.6 ± 8.0 years. Most were seropositive for RF and/or ACPA (74.4%), and comorbidities were highly prevalent (93.6%). Clinical remission was observed in 42.3% and ultrasound remission in 56.4%, with no statistically significant differences between JAKi groups. Among 50 patients meeting remission by either definition, 30 (60%) fulfilled both criteria, 11 (22%) had ultrasound remission only, and 9 (18%) met clinical remission without sonographic confirmation. Discordant cases were often associated with osteoarthritis, fibromyalgia, mood disorders, and elevated inflammatory markers.

Conclusions

JAKi were effective in achieving remission in many RA patients. Ultrasound revealed residual synovitis despite clinial remission and, conversely, silent remission in cases not meeting DAS28-CRP criterion, reinforcing its value for accurate monitoring and personalized therapeutic decisions. No meaningful clinical or ultrasonographic differences were observed between the various JAK inhibitors, indicating comparable perfomance across agents in routine practice.

Schlagwörter

Stichwörter der Autor:innen

DAS28-CRPJAKIJanus kinase inhibitorsTargeted TherapyTreat-To-Targetclinical remissiondisease activitymusculoskeletal ultrasoundrheumatoid arthritisultrasonographic remission

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, Instituto de Investigación Valdecilla (IDIVAL), 39008 Santander, Spain.
  • Division of Immunology, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), 39008 Santander, Spain.
  • Division of Rheumatology, Hospital Comarcal de Laredo, 39770 Laredo, Spain.
  • Division of Rheumatology, Hospital de Sierrallana, 39300 Torrelavega, Spain.

ORCID-Profile: Carmen Lasa-Teja, Lara Sánchez-Bilbao, Javier Loricera, Iñigo González-Mazón, Carmen Álvarez-Reguera, Alba Herrero-Morant, Jose Luis Martín-Varillas, Montserrat Santos-Gómez, Marcos López-Hoyos, Ricardo Blanco

Zitieren

APA

Lasa-Teja, C., Fernández-Cabero, J. J., Sánchez-Bilbao, L., Loricera, J., González-Mazón, I., Álvarez-Reguera, C., Herrero-Morant, A., Corrales-Martínez, A., Portilla-González, V., Martín-Varillas, J. L., Pérez-Garrido, L., Santos-Gómez, M., López-Hoyos, M., & Blanco, R. (2025). Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study. Journal of Clinical Medicine, 15(1), 278. https://doi.org/10.3390/jcm15010278

Vancouver

Lasa-Teja C, Fernández-Cabero JJ, Sánchez-Bilbao L, Loricera J, González-Mazón I, Álvarez-Reguera C, et al. Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study. Journal of Clinical Medicine. 2025;15(1):278. doi:10.3390/jcm15010278

BibTeX
@article{LasaTeja2025,
  author = {Lasa-Teja, Carmen and Fernández-Cabero, Juan José and Sánchez-Bilbao, Lara and Loricera, Javier and González-Mazón, Iñigo and Álvarez-Reguera, Carmen and Herrero-Morant, Alba and Corrales-Martínez, Alfonso and Portilla-González, Virginia and Martín-Varillas, Jose Luis and Pérez-Garrido, Laura and Santos-Gómez, Montserrat and López-Hoyos, Marcos and Blanco, Ricardo},
  title = {Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {278},
  doi = {10.3390/jcm15010278}
}
Kostenlos starten →